Project Grant R01CA301371
- Federal Project Grant Award Summary The University of Wisconsin–Madison received a $630,171 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 12, 2025 through July 31, 2030. This award supports the development of a first-in-class radiopharmaceutical therapy (RPT) targeting triple-negative breast cancer (TNBC), an aggressive cancer subtype with a five-year survival rate of 12% for metastatic cases. The research...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $988,224 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to advance treatment strategies for head and neck cancer patients with competing health risks through multi-center randomized clinical trials. The four-year award, effective September 1, 2025 through August 31, 2029, supports the principal investigator's clinical research program focused on developing novel alternative therapeutic...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $427,625 Project Grant to The Washington University (awarded February 6, 2026, completion February 5, 2028) under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop and evaluate radiation-guided theranostic agents for monitoring treatment response in head and neck squamous cell carcinoma (HNSCC). The research focuses on leveraging radiation-inducible tumor-associated...
- Federal Project Grant Award Summary The Medical College of Wisconsin, Inc. received a $632,314 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded April 1, 2026, with a completion date of March 31, 2031. This award supports research and development of gallium maltolate (GAM), an iron-mimetic metallocompound, as a novel therapeutic treatment for difficult-to-treat pediatric central nervous system (CNS) tumors, specifically...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $216,013 to the University of Wisconsin-Madison under the Cancer Biology Research program (CFDA 93.396), effective September 1, 2025 through August 31, 2027. This award supports fundamental research investigating the mechanisms by which caspases (cellular enzymes) and antiviral interferon (IFN) responses influence Kaposi's Sarcoma-Associated Herpesvirus (KSHV) tumorigenesis. The research addresses a...
- Federal Grant Award Summary The University of Wisconsin–Madison received a $603,981 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), effective August 18, 2025, with completion targeted for July 31, 2030. This award supports the development and clinical validation of integrated artificial intelligence (AI) biomarkers combining genomic and digital pathology analysis to improve patient selection for high-risk prostate...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This research initiative focuses on understanding and overcoming treatment resistance in locally advanced rectal cancer (LARC) patients undergoing total neoadjuvant therapy (TNT)—a combined treatment regimen consisting of radiation therapy,...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) for the period of August 1, 2025, through July 31, 2030. The research focuses on developing antigen-specific radiosensitization through antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance the therapeutic index of radiotherapy. The project centers on two...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $662,682 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on June 4, 2025, with an ultimate completion date of May 31, 2030. This award funds research investigating the prognostic and therapeutic roles of voltage-gated potassium channels in managing KIT mutant gastrointestinal stromal tumors (GISTs). The project will deliver a Phase 1 neoadjuvant...
- Federal Grant Award Summary The National Cancer Institute awarded a $2.58M Project Grant to the University of Wisconsin–Madison under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on August 11, 2025, with completion targeted for July 31, 2030. This award supports research investigating molecular drivers and therapeutic susceptibilities in lineage state transitions of metastatic castrate-resistant prostate cancer (MCRPC). The research program addresses the critical clinical...
Grant Award Summary The University of Wisconsin–Madison received a $634,644 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on March 12, 2026, with completion targeted for February 28, 2031. The research project investigates the treatment of neuroinflammation to remediate chemoradiation-induced dysphagia (difficulty swallowing) in head and neck cancer patients. Using a rat animal model, the study evaluates the combined therapeutic approach of glibenclamide (GLC) pharmaceutical treatment and tongue exercise protocols to mitigate radiation-induced peripheral neuropathy (RIPN) and associated swallowing dysfunction resulting from chemoradiation therapy to the base of the tongue. The project has two primary research objectives: (1) to test whether GLC treatment combined with tongue exercise improves functional measures of swallowing in the rat model of head and neck chemoradiation, and (2) to determine whether this combined intervention mitigates inflammation in both the peripheral and central nervous systems following chemoradiation exposure. By establishing optimal treatment modalities and timelines for addressing the neurogenic sources of post-treatment dysphagia, this research aims to translate findings into improved clinical outcomes and quality of life for cancer patients experiencing swallowing complications from cancer treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $634.6k | 3/12/26 |